A Randomized, Double-blind, Placebo-Controlled, Four- Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-5788 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2019
At a glance
- Drugs ONO-5788 (Primary) ; Octreotide
- Indications Acromegaly
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Ono Pharmaceutical
- 03 Jan 2019 Planned End Date changed from 25 Jan 2019 to 25 Apr 2019.
- 03 Jan 2019 Planned primary completion date changed from 25 Jan 2019 to 25 Apr 2019.
- 05 Jul 2018 New trial record